secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2023-11-30T23:59:59+00:00
Accession:  0001104659-23-122241
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie to acquire ImmunoGen for $31.26/share ($10.1B total) – adds ovarian cancer therapy ELAHERE
--------------------------------------------------------------------------------

- Transaction valued at $31.26 per share in cash, total equity value approx $10.1B.
- Premium of ~95% to ImmunoGen's closing price on Nov 29, 2023.
- Expected to close mid-2024; negatively impact 2024 EPS by ~$0.13, 2025 by ~$0.16, accretive from 2027.
- Key asset: ELAHERE, a first-in-class ADC approved for platinum-resistant ovarian cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000110465923122241/0001104659-23-122241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000110465923122241/tm2331814d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-122241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer